Natera Inc Stock
Price
Target price
€231.40
€231.40
1.070%
2.5
1.070%
-
22.07.26 / Tradegate
WKN: A14VPJ / Name: Natera / Stock / Healthcare Equipment & Supplies / Small Cap /
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Your prediction
Natera Inc Stock
There is an upward development for Natera Inc compared to yesterday, with an increase of €2.50 (1.070%).
Pros and Cons of Natera Inc in the next few years
Pros
?
B****
?
M***** P*******
?
G***** c******* t* c**********
Cons
?
S********** s********
?
C******** o* t** e**********
?
W********* I********* f** t** n*** y****
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Natera Inc vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Natera Inc | 1.070% | -4.380% | 15.584% | 92.833% | 17.462% | 440.654% | 142.304% |
| Lantheus Holdings Inc | -2.960% | 2.230% | -1.398% | 48.960% | 60.315% | 16.548% | - |
| IRadimed Corp | -1.180% | 5.590% | 5.590% | 76.349% | 2.410% | - | - |
| Orasure Tech | 4.270% | -6.557% | -3.390% | 23.913% | 66.019% | -12.755% | -61.057% |
News
Billionaire Stanley Druckenmiller's Top Holding Isn't Nvidia. Instead, It's This Under-the-Radar Stock That Wall Street Loves.
He's a retired hedge fund manager, but people still want to know what billionaire Stanley Druckenmiller is doing with his money. The answer? Investing in the medical diagnostic company Natera
Here's Billionaire Stanley Druckenmiller's Top Holding (Hint: It's Not Alphabet or Nvidia)
Your personal portfolio doesn't necessarily need to mirror a billionaire investor's holdings. But let's face it -- they manage billion-dollar portfolios for a reason.
And that's what makes Stanley
Allogene Therapeutics Q1 Earnings Call Highlights
Allogene Therapeutics (NASDAQ:ALLO) said its first quarter of 2026 was marked by early clinical progress for its lead allogeneic CAR-T programs and a
